MiniMed presented new clinical evidence showing that people with type 1 diabetes using the MiniMed Smart MDI system who responded to more missed-dose and high-glucose alerts had, on… read more.
Eli Lilly and Company announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control… read more.
Eli Lilly and Company announced the FDA approval of Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults… read more.
Zealand Pharma A/S announces the initiation of the global registrational Phase 3 Zupreme program, evaluating the efficacy and safety of once-weekly petrelintide versus placebo in people with overweight… read more.
Novo Nordisk announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo’s next innovation… read more.
A Johns Hopkins Medicine study reports evidence that time-restricted eating (TRE) — a form of intermittent fasting that involves only eating during a consistent, daily 8- to 10-hour… read more.
Abbott announced FDA authorization of its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology. The new biowearable is designed to alert people living with… read more.
A multicenter randomized clinical trial led by researchers from the Pain Outcomes Lab at Wake Forest University School of Medicine found that high-frequency spinal cord stimulation significantly reduced pain and… read more.
Eli Lilly and Company announced that the FDA approved Mounjaro (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV)… read more.
Various forms of physical exercise may help prevent diabetes during pregnancy (or gestational diabetes), but data are limited. In a randomized clinical trial published in Acta Obstetricia et Gynecologica… read more.
Personal care products are among the largest everyday sources of exposure to endocrine-disrupting chemicals, and high schoolers who follow social media influencers or watch beauty tutorials seem to… read more.
Ultragenyx Pharmaceutical announced that the FDA granted accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), also known as DTX 401, in adult and pediatric patients eight years and older with… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
